Trial Profile
Clinical Study of the Safety and Efficacy of BCMA-CART Cell in the Treatment of Relapsed or Refractory Multiple Myeloma (MM)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Mar 2018
Price :
$35
*
At a glance
- Drugs CAR-BCMA-T-cell (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Innovative Cellular Therapeutics
- 05 Mar 2018 New trial record